Ondansetron

Cleft palate

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S2757
R3950		 Zambelli-Weiner (Unexposed control, NOS), 2019 Cleft palate 1st trimester nested case control unexposed (general population or NOS) Adjustment: Yes 1.46 [0.81;2.65] 11/889   1,068/114,174 1,079 889
ref
S2852
R3875		 Huybrechts (Control exposed to other treatment), 2018 Cleft Palate 1st trimester retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: Yes 1.25 [0.89;1.75]
excluded (control group) 		46/55,579   120/185,699 166 55,579
ref
S2844
R3845		 Huybrechts (Unexposed control), 2018 Cleft Palate 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 1.20 [0.94;1.55] 65/88,446   987/1,727,546 1,052 88,446
ref
S2853
R3963		 Parker, BDS study, 2018 Cleft palate only 1st trimester case control unexposed, sick Adjustment: Yes 0.50 [0.30;1.00] 11/386   276/5,774 287 386
ref
S2756
R3678		 Parker, NBDPS study, 2018 Cleft palate only 1st trimester case control unexposed, sick Adjustment: Yes 1.60 [1.10;2.30] 40/252   378/3,433 418 252
ref
S2746
R3897		 Pasternak, 2013 Cleft palate 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: No 0.80 [0.04;16.67] C 0/1,233   2/4,932 2 1,233
ref
S2747
R3644		 Anderka, 2012 Cleft palate 1st trimester case control unexposed, sick Adjustment: Yes 2.37 [1.18;4.76] 11/55   514/4,479 525 55
ref
Total 6 studies 1.26 [0.87;1.82] 3,363 91,261
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Zambelli-Weiner (Unexposed control, NOS), 2019Zambelli-Weiner, 2019 1 1.46[0.81; 2.65]1,07988917%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Huybrechts (Unexposed control), 2018Huybrechts, 2018 2 1.20[0.94; 1.55]1,05288,44627%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Parker, BDS study, 2018Parker, BDS study, 2018 0.50[0.30; 1.00]28738617%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Parker, NBDPS study, 2018Parker, NBDPS study, 2018 1.60[1.10; 2.30]41825223%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Pasternak, 2013Pasternak, 2013 0.80[0.04; 16.67]21,2331%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Anderka, 2012Anderka, 2012 2.37[1.18; 4.76]5255515%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (6 studies) I2 = 65% 1.26[0.87; 1.82]3,36391,2610.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Unexposed control, NOS; 2: Unexposed control;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.20[0.93; 1.54]1,05489,6790%NAHuybrechts (Unexposed control), 2018 Pasternak, 2013 2 case control studiescase control studies 1.29[0.71; 2.33]2,3091,58278%NAZambelli-Weiner (Unexposed control, NOS), 2019 Parker, BDS study, 2018 Parker, NBDPS study, 2018 Anderka, 2012 4 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.23[0.98; 1.55]2,13390,5680%NAZambelli-Weiner (Unexposed control, NOS), 2019 Huybrechts (Unexposed control), 2018 Pasternak, 2013 3 unexposed, sickunexposed, sick 1.24[0.54; 2.83]1,23069385%NAParker, BDS study, 2018 Parker, NBDPS study, 2018 Anderka, 2012 3 Tags Adjustment   - No  - No 0.80[0.04; 16.67]21,233 -NAPasternak, 2013 1   - Yes  - Yes 1.27[0.86; 1.86]3,36190,02872%NAZambelli-Weiner (Unexposed control, NOS), 2019 Huybrechts (Unexposed control), 2018 Parker, BDS study, 2018 Parker, NBDPS study, 2018 Anderka, 2012 5 All studiesAll studies 1.26[0.87; 1.82]3,36391,26165%NAZambelli-Weiner (Unexposed control, NOS), 2019 Huybrechts (Unexposed control), 2018 Parker, BDS study, 2018 Parker, NBDPS study, 2018 Pasternak, 2013 Anderka, 2012 60.25.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-3.63.91.8590.000Zambelli-Weiner (Unexposed control, NOS), 2019Huybrechts (Unexposed control), 2018Parker, BDS study, 2018Parker, NBDPS study, 2018Pasternak, 2013Anderka, 2012

Asymetry test p-value = 0.9279 (by Egger's regression)

slope=0.2628 (0.3444); intercept=-0.1480 (1.5373); t=0.0963; p=0.9279

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 2852

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.23[0.98; 1.55]2,13390,5680%NAZambelli-Weiner (Unexposed control, NOS), 2019 Huybrechts (Unexposed control), 2018 Pasternak, 2013 3 unexposed, sick controlsunexposed, sick controls 1.24[0.54; 2.83]1,23069385%NAParker, BDS study, 2018 Parker, NBDPS study, 2018 Anderka, 2012 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.25[0.89; 1.75]16655,579 -NAHuybrechts (Control exposed to other treatment), 2018 10.510.01.0